Ends on

The title should objectively describe the study and should not include proprietary drug names. Abstracts should not be more than 250 words including title and abstract body excluding spaces, authors, and affiliations. One brief graph, illustration or table is allowed and is not included in the total word count. All abstracts should be structured in four sections:

  • Background
  • Methods
  • Results
  • Conclusions

Authors and Affiliations
The maximum number of authors allowed is twenty. Academic degrees and professional positions (such as Medical Director) should not be included. Pharmaceutical industry authors are allowed to present abstracts. A non-named author can present a poster if written permission to do so is provided by the lead author. 

“Trials in Progress” Abstracts
Please indicate that the abstract is from a trial in progress. Abstracts submitted in this category are ongoing and should not include outcomes data or results. You may include:

  • Abstracts in all phases of clinical research (phases I to III) may be submitted
  • Any abstract submitted as a trial in progress are ongoing trials, open to enrollment, that have not reached any protocol-specific endpoints for analysis, and consequently will only require the completion of the Background and Trial Design sections.
  • If endpoint data are to be presented, please submit under the "Abstracts of Clinical Trials with Results to be Presented" category

Abstracts in the following categories will also be considered for presentation:

  • Basic science (preclinical research)
  • Pharmacokinetics/pharmacodynamics
  • Health economic outcomes research (HEOR)
  • Case series of  ≥5 patients (case series of <5 patients and single-patient case reports are not accepted)
  • Encore presentations (poster must include where it was originally presented)
  • Late-breaking abstracts
  • Literature reviews
  • Research abstracts funded by for-profit organizations, including biotech and pharma
  • Clinical trials with results 

Abstract Selection Process and Presentation

  • Abstracts will be reviewed by the IKCS Scientific Program Committee.
  • All accepted abstracts are encouraged to present their posters in person at IKCS 2021 and will receive complimentary registration for the conference. Accepted abstracts will be displayed at the live meeting throughout the entirety of IKCS 2021. During the networking reception and poster walk to be held the evening of Friday, November 5th. Poster presenters are encouraged to be onsite for this event to answer any questions about their abstract. 
  • Abstracts accepted for oral presentation as part of the IKCS 2021 agenda will receive complimentary registration and a travel award. 
  • All accepted abstracts will be published in Kidney Cancer Journal

Merit Awards for Best Abstracts Submitted
The IKCS Scientific Program Committee will select authors of submitted abstracts to receive a merit award for the best original submissions. 

  • First place: $500
  • Second place: $250
  • Third place: $100 

Please note: Encore presentations will not be eligible to receive the merit awards. 

Submission deadline is September 17, 2021 at 11:59 p.m. CST.
Accepted abstract authors will be notified the week of October 4th.

For any questions, please email info@kcameetings.org.

We use Submittable to accept and review our submissions.